Join me and Drs Kahl, Sehn and Westin at @gotoPER’s #ASH20 FSS Program today at 11AM PT.

Clinical trial opening soon. CRM1 inhibitor anti-tumor activity is enhanced with salicylates by S-phase arrest and impaired DNA-damage repair | Blood | American Society of Hematology ashpublications.org/blood/ar… @WitzigLab @MayoClinic @JithmaA @VincentRK